ATED Therapeutics Named Finalist for the 2026 Asper PrizeJerusalem, Israel — May 20, 2026ATED Therapeutics announced today that it has been selected as a finalist for the 2026 Asper Prize, the Hebrew University of Jerusalem’s flagship award recognizing breakthrough innovation and global impact. This distinction places ATED Therapeutics among a select group of ventures chosen for their scientific excellence, technological originality, and potential to address major global health challenges.ATED Therapeutics has developed a simple blood test for Parkinson’s disease, leveraging tRFs (transfer RNA fragments) as a novel and highly sensitive biomarker. This breakthrough aims to enable earlier, more accurate detection of Parkinson’s disease—an area where current diagnostic tools remain limited.The Asper Prize, awarded annually by ASPER–HUJI Innovate, highlights startups founded by or connected to the Hebrew University community that demonstrate exceptional promise in fields aligned with the UN Sustainable Development Goals. Finalists are evaluated by a panel of leading venture capitalists, industry executives, and academic experts.“We are honored to be named a finalist for the 2026 Asper Prize,” said Jeff R. Swarz, Ph.D., CEO of ATED Therapeutics. “This recognition underscores the urgency and importance of our mission to advance a new era in Parkinson’s disease diagnosis.”As a finalist, ATED Therapeutics will present its technology at the Hebrew University Board of Governors meeting, where the winner will be selected and awarded a 100,000 ILS equity‑free prize.About ATED Therapeutics: ATED Therapeutics is a biotechnology company developing next‑generation diagnostic and therapeutic solutions for Parkinson's disease by combining advanced molecular research with innovative biomarker discovery, the company aims to bring transformative tools and treatments to patients worldwide.Media Contact ATED Therapeutics Communications Team jswarz@ated-diagnostics.com